Valeant to Pay Up to $20M for Nicox's U.S. Ophthalmic Dx Unit

Monday, November 17, 2014

Source: Clinica

Valeant Pharmaceuticals has agreed to acquire Nicox's U.S. ophthalmic diagnostics division for a $10 million upfront payment, plus as much as $10 million in potential milestone fees. The sale is expected to allow Nicox to concentrate on expanding its ophthalmic therapeutics portfolio.

View All News »